ARDS Clinical Trial
Official title:
Ultra-Low Tidal Volume Mechanical Ventilation in ARDS Through ECMO (ULTIMATE) Pilot Randomized Trial
Primary Research Question for the Full ULTIMATE Randomized Clinical Trial (RCT): What is the effect of ultra-protective ventilation facilitated by extracorporeal membrane oxygenation (ECMO) versus best current conventional ventilation (CV) on all-cause hospital mortality among patients with early moderate-severe acute respiratory distress syndrome (ARDS)? Secondary Research Questions: Among patients with early moderate-severe ARDS, what is the effect of ultra-protective ventilation versus CV on: (1) duration of mechanical ventilation; (2) duration of ICU and hospital stay; (3) organ dysfunction; (4) barotrauma; and (5) mortality at other time-points (ICU discharge, 28-day, 60-day)? The ULTIMATE Pilot Study: Before embarking on a definitive multinational trial to address the questions listed above, the ULTIMATE Pilot Study has these 3 specific feasibility objectives: 1. To assess adherence to our explicit mechanical ventilation protocols, with particular focus on delivered tidal volumes in both groups; 2. To estimate the rate of patient recruitment and understand barriers to recruitment; and 3. To measure and understand the reasons for crossovers or rescue by ECMO in the control group. In addition, we will monitor safety issues, recording serious adverse events in both groups.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04435613 -
Clinical and Physiological Assessment of a Nearly Ultra-protective Lung Ventilation Strategy: A Quasi-experimental Preliminary Study in ARDS Patients
|
N/A | |
| Enrolling by invitation |
NCT05020210 -
Effect of Early Treatment With Sivelestat Sodium in ARDS Patients
|
||
| Completed |
NCT04468971 -
REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia
|
Phase 1 | |
| Completed |
NCT04505592 -
Tenecteplase in Patients With COVID-19
|
Phase 2 | |
| Completed |
NCT04493242 -
Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS
|
Phase 2 | |
| Withdrawn |
NCT04909879 -
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome
|
Phase 2 | |
| Completed |
NCT02265198 -
Relationship of Pulmonary Contusion to Pulmonary Inflammation and Incidence of Acute Respiratory Distress Syndrome
|
N/A | |
| Completed |
NCT01949272 -
Optimization of PEEP for Alveolar Recruitment in ARDS
|
N/A | |
| Not yet recruiting |
NCT01668368 -
Goal Directed Mechanical Ventilation Aimed at Optimal Lung Compliance
|
N/A | |
| Completed |
NCT01881061 -
Lung Sonography in Patients With Acute Respiratory Distress Syndrome in Intensive Care Unit
|
N/A | |
| Completed |
NCT00808691 -
Microcirculation and Oxidative Stress in Critical Ill Patients in Surgical Intensive Care Unit
|
N/A | |
| Completed |
NCT05035589 -
The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia
|
||
| Recruiting |
NCT04764032 -
Right Ventricular Dysfunction in Ventilated Patients With COVID-19
|
||
| Completed |
NCT04556513 -
Functional Recovery From Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19: Influence of Socio-Economic Status
|
||
| Recruiting |
NCT06036056 -
NMR Based Metabolomics Kinetics in ARDS Patients
|
||
| Recruiting |
NCT04503876 -
Effects of End-expiratory Positive Pressure Optimization in Intubated Patients With Healthy Lung or Acute Respiratory Distress Syndrome
|
N/A | |
| Recruiting |
NCT04643691 -
Losartan and Spironolactone Treatment for ICU Patients With COVID-19 Suffering From ARDS
|
Phase 2 | |
| Completed |
NCT04395911 -
Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections
|
N/A | |
| Not yet recruiting |
NCT05341687 -
Prognostic Value of Respiratory System Compliance Under VV-ECMO on 180-day Mortality in COVID-19 ARDS.
|
||
| Recruiting |
NCT05056090 -
Effect of Prone Positioning on Mortality in Patients With Mild to Moderate Acute Respiratory Distress Syndrome.
|
N/A |